Please use this identifier to cite or link to this item:
Title: Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
Austin Authors: Miller, Aaron E;Xu, Xianhao;Macdonell, Richard A L ;Vucic, Steve;Truffinet, Philippe;Benamor, Myriam;Thangavelu, Karthinathan;Freedman, Mark S
Affiliation: Multiple Sclerosis Research Unit, Department of Neurology, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Department of Neurology, Beijing Hospital, Beijing, China
Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
Faculty of Medicine, University of Sydney, Sydney, Australia
R&D, Sanofi, Chilly-Mazarin, France
Global Pharmacovigilance & Epidemiology, Sanofi, Chilly-Mazarin, France
Biostatistics, Sanofi, Cambridge, MA, United States
Issue Date: Jan-2019 2018-10-20
Publication information: Journal of Clinical Neuroscience 2019; 59: 229-231
Abstract: In the phase 3 TOWER (NCT00751881) study, teriflunomide 14 mg significantly reduced annualized relapse rate (ARR) and risk of 12-week confirmed disability worsening (12-w CDW) vs placebo in patients with relapsing forms of MS (RMS). The TOWER population included an appreciable proportion of Asian patients. Reductions in ARR and 12-w CDW associated with teriflunomide 14 mg were comparable between the Asian and overall populations, as were the rates for adverse events and serious adverse events, with no new or unexpected safety findings. These observations provide further evidence to support the clinical benefits and safety profile of teriflunomide in a broad range of patients with RMS.
DOI: 10.1016/j.jocn.2018.09.012
PubMed URL: 30348586
Type: Journal Article
Subjects: Clinical trial
Disease-modifying therapy
Multiple sclerosis
Phase 3
Subgroup analysis
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 6, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.